OVID THERAPEUTICS INC (OVID) Forecast, Price Target & Analyst Ratings
NASDAQ:OVID • US6904691010
2.13 USD
-0.01 (-0.47%)
At close: Mar 10, 2026
2.0649 USD
-0.07 (-3.06%)
After Hours: 3/10/2026, 8:00:03 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OVID THERAPEUTICS INC (OVID).
Forecast Snapshot
Consensus Price Target
$4.26
+ 99.93% Upside
Next Earnings Forecast
Release DateMar 16, 2026
PeriodQ4 / 2025
EPS Estimate-$0.12
Revenue Estimate13.597K
ChartMill Buy Consensus
87.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.26
Upside
+ 99.93%
From current price of $2.13 to mean target of $4.26, Based on 16 analyst forecasts
Low
$2.02
Median
$4.59
High
$7.35
Price Target Revisions
1 Month
0.00%
3 Months
-3.87%
Price Target Summary
16 Wall Street analysts provided a forecast for the next 12 months for OVID. The average price target is 4.26 USD. This implies a price increase of 99.93% is expected in the next year compared to the current price of 2.13.
The average price target has been revised downward by 3.87% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.50%
OVID was analyzed by 16 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about OVID.
In the previous month the buy percentage consensus was at a similar level.
OVID was analyzed by 16 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-22 | LifeSci Capital | Initiate | Outperform |
| 2025-12-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-11 | Roth Capital | Initiate | Buy |
| 2025-11-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-17 | Leerink Partners | Initiate | Outperform |
| 2025-05-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-24 | BTIG | Maintains | Buy -> Buy |
| 2025-03-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-01-29 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2024-12-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-18 | BTIG | Maintains | Buy -> Buy |
| 2024-06-18 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-06-18 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-06-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-07 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-04-30 | B. Riley Securities | Initiate | Buy |
| 2024-04-29 | HC Wainwright & Co. | Initiate | Buy |
| 2024-04-05 | Wedbush | Initiate | Outperform |
| 2023-12-21 | BTIG | Initiate | Buy |
| 2023-06-14 | JonesTrading | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 16, 2026
PeriodQ4 / 2025
EPS Estimate-$0.12
Revenue Estimate13.597K
Revenue Q2Q-82.11%
EPS Q2Q6.63%
Number of Analysts12
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
1.96%
Next Earnings Summary
OVID is expected to report earnings on 3/16/2026. The consensus EPS estimate for the next earnings is -0.12 USD and the consensus revenue estimate is 13.60K USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.5M -99.28% | 391.7K -73.89% | 566K 44.50% | 6.665M 1,077.56% | 170.483K -97.44% | 95.88K -43.76% | 130.56K 36.17% | 7.775M 5,855.12% | 62.526M 704.19% | 203.56M 225.56% | 400.71M 96.85% | 248.02M -38.10% | |
| EBITDA YoY % growth | -55M -144.21% | -57.685M -4.88% | -61.272M -6.22% | -58.65M 4.28% | -53.876M 8.14% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -55.5M -144.69% | -59.282M -6.81% | -61.885M -4.39% | -42.815M 30.81% | -58.476M -36.58% | -81.478M -39.34% | -92.132M -13.08% | -96.119M -4.33% | -44.767M 53.42% | 28.048M 162.65% | 208.78M 644.37% | 45.885M -78.02% | |
| Operating Margin | -3,700.00% | -15,134.41% | -10,933.75% | -642.39% | -34,300.07% | -84,979.36% | -70,566.88% | -1,236.25% | -71.60% | 13.78% | 52.10% | 18.50% | |
| EPS YoY % growth | -0.77 -137.93% | -0.75 2.60% | -0.38 49.33% | -0.50 -30.82% | -0.47 6.32% | -0.55 -17.44% | -0.40 26.01% | -0.45 -10.92% | -0.49 -10.23% | 1.35 372.16% | 1.65 22.73% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 6.63% | -0.12 15.12% | -0.11 -91.54% | -0.12 32.10% | -0.12 0.84% |
| Revenue Q2Q % growth | 13.597K -82.11% | 112.2K -13.69% | 112.2K -98.21% | 112.2K -15.00% | 95.197K 600.15% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.767M -19.07% | -13.519M -7.72% | -14.464M -185.11% | -15.448M -23.36% | -16.712M -30.90% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-12.90%
EPS Next 5 Year
-3.38%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-47.73%
Revenue Next 5 Year
63.21%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
OVID THERAPEUTICS INC / OVID Forecast FAQ
What do analysts expect the price target to be for OVID THERAPEUTICS INC (OVID)?
16 analysts have analysed OVID and the average price target is 4.26 USD. This implies a price increase of 99.93% is expected in the next year compared to the current price of 2.13.
When does OVID THERAPEUTICS INC (OVID) report earnings?
OVID THERAPEUTICS INC (OVID) will report earnings on 2026-03-16, after the market close.
What are the consensus estimates for OVID stock next earnings?
The consensus EPS estimate for the next earnings of OVID THERAPEUTICS INC (OVID) is -0.12 USD and the consensus revenue estimate is 13.60K USD.
Can you provide the consensus rating for OVID THERAPEUTICS INC stock?
The consensus rating for OVID THERAPEUTICS INC (OVID) is 87.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.